NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NYSE American · Biotechnology · USD

Endovia Health Sciences, Inc. (EDVA) Stock Analysis

Endovia Health Sciences, Inc. (EDVA) is a Biotechnology stock listed on NYSE American and quoted in US Dollar.

Last Updated: October 21, 2026

EDVA

$0.15

+$0.01 (+5.52%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare EDVA with… →

EDVA Key Statistics

As of Oct 21, 2026
Trading
Open
$0.15
Previous Close
$0.15
Day's Range
0.15–0.16
52-Week Range
0.13–13.40
Volume
586.97K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−1.15
Valuation
Market Cap
$1.70M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
52.82
EPS (ttm)Profit attributable to each share over the last twelve months.
−21.94
Financials (FY)
Revenue (FY)
$73.07K−90.88%
Net Income (FY)
−$25.23M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
11.08M
1-Year Return
−97.98%
Dividend and dates
Avg Volume
4.46M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, EDVA closed at $0.15, −97.98% over 1 year.

Endovia Health Sciences, Inc. (EDVA) has a market capitalization of $1.70M.

In fiscal 2025, EDVA reported revenue of $73.07K.

EDVA Stock Return by Calendar Year

Endovia Health Sciences, Inc. (EDVA) return since Feb 2019: what $10,000 became

1 year
$10,000 $202
−97.98%
5 years
$10,000 $6
−99.94%
Since Feb 2019
$10,000 $6
−99.94%

If you had invested $10,000 in Endovia Health Sciences, Inc. (EDVA) at the close on February 5, 2019, the earliest close on record here, it would have been worth $6 at the close on October 21, 2026: −99.94% in total, −61.61% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−94.46%
2025−89.29%
2024−70.83%
2023−42.56%
2022−17.72%
2021−66.72%
2020+37.65%
2019 (partial year)+66.67%

As of October 21, 2026.

EDVA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$73.07K−$25.23M−34,537.0%
2024$801.27K−$23.76M−2,964.9%
2023$18.85M−$21.00M−111.4%
2022$18.09M−$21.69M−119.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$73.07K$16.90K−$14.19M−$25.23M−34,537.0%
2024$801.27K−$119.80K−$9.90M−$23.76M−2,964.9%
2023$18.85M$5.57M−$15.29M−$21.00M−111.4%
2022$18.09M$5.92M−$21.39M−$21.69M−119.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

EDVA Valuation vs Biotechnology Median

Median of 608 stocks
MetricEDVABiotechnology medianvs median
P/S ratio52.8213.304.0x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Endovia Health Sciences, Inc. (EDVA) carries a market capitalisation of $1.70M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 1 employees.

EDVA last closed at $0.15 on October 21, 2026. That is +$0.01 (+5.52%) against the previous close. Over the past 52 weeks the price has ranged from $0.13 to $13.40. The latest close sits 14.18% above that 52-week low.

Financial Health

In fiscal 2025, Endovia Health Sciences, Inc. reported revenue of $73.07K. That is −90.88% against the prior fiscal year, when revenue was $801.27K. The same year closed with a net loss of $25.23M. Earnings per share on a trailing basis come to −21.94.

Across the 4 fiscal years on file, revenue moves from $18.09M in 2022 to $73.07K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 52.82. On price-to-sales that is 4 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Over the trailing twelve months the total return is −97.98%. Across 5 years the annualized return works out at −77.56%. The reported beta is −1.15. Daily returns over the trailing 7 years annualize to a volatility of 164.16%.

Growth & Income

The record shows no dividend for EDVA.

Across the complete calendar years on file, 2020 returned +37.65% and 2025 returned −89.29%. Of the 6 complete calendar years on file, 1 finished higher. So far in 2026 the total return is −94.46%.

Peer Comparison

Endovia Health Sciences, Inc. (EDVA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Endovia Health Sciences, Inc. EDVA $1.70M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Endovia Health Sciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Endovia Health Sciences, Inc.

Endovia Health Sciences, Inc. develops a diversified cannabinoid health sciences platform that translates science into regulated therapies and trusted health and wellness products for people and animals in Ireland, United Kingdom, Australia, and Latin America. Its product includes CannEpil a pharmaceutical-grade cannabinoid formulation comprising cannabidiol and tetrahydrocannabinol isolates in an oral liquid solution. Endovia Health Sciences, Inc. formerly known as Splash Beverage Group, Inc. The company is based in Fort Lauderdale, Florida.

Visit website →